Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) saw a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 92,000 shares, a drop of 58.8% from the May 31st total of 223,200 shares. Based on an average daily volume of 1,476,400 shares, the days-to-cover ratio is presently 0.1 days.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on BAYRY. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, March 7th. The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a research note on Thursday, May 30th. They issued a “neutral” rating for the company. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold”.
Get Our Latest Research Report on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Trading Up 1.0 %
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported $0.77 EPS for the quarter. The firm had revenue of $14.95 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. Research analysts predict that Bayer Aktiengesellschaft will post 1.36 EPS for the current fiscal year.
Bayer Aktiengesellschaft Cuts Dividend
The firm also recently declared a dividend, which was paid on Monday, May 13th. Shareholders of record on Tuesday, April 30th were paid a dividend of $0.0191 per share. The ex-dividend date was Monday, April 29th. Bayer Aktiengesellschaft’s dividend payout ratio is -2.30%.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
See Also
- Five stocks we like better than Bayer Aktiengesellschaft
- What is Short Interest? How to Use It
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Breakout Stocks: What They Are and How to Identify Them
- MarketBeat Week in Review – 6/24 – 6/28
- Ride Out The Recession With These Dividend Kings
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.